Analysis: Part 2 Suppose there had been some disagreement among the managers as to the responsiveness of some of the drugs to changes in sales effort. In partic- ular, some managers felt that the estimates of Praxonil's potential were a bit conservative. Others felt that Didex and Zynalar would have a differ- ent responsiveness to sales force effort. Finally, others felt that Nasaprax's responsiveness needed to be reconsidered in light of its status as a new product. This resulted in the following sales response estimates (given as a percentage of the Strategic Plan revenue numbers): No Calls One-Half Strategic Plan 50% More Saturation Zynapra 47% 68% 100% 126% 152% Praxonil 15% 48% 100% 132% 149% Norzyn 31% 63% 100% 115% 125% Nurzyn 45% 70% 100% 105% 110% Didex 61% 88% 100% 122% 132% Zynalar 65% 84% 100% 107% 111% Nasaprax 15% 60% 100% 150% 180% How sensitive are your previous findings to these changes in the man- agers' judgments? Note that the revised parameter estimates for the AD- BUDG functions ( {x,[S .Y ,0) are not provided. You will need to compute them using the above data and the method covered in the class notes. (Use 2 and 1000 as starting values for